Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride hemihydrate, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of:,? major depression and for the prevention of relapse of depressive symptoms;,? obsessive compulsive disorder and for the prevention of relapse of ocd;,? panic disorder and for the prevention of relapse of panic disorder;,? social anxiety disorder/social phobia; and,? generalised anxiety disorder;,? posttraumatic stress disorder.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - rivastigmine hydrogen tartrate -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - rivastigmine hydrogen tartrate -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - rivastigmine hydrogen tartrate -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - rivastigmine hydrogen tartrate -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; lactose monohydrate; magnesium stearate; disodium edetate; sodium starch glycollate; guar gum; colloidal anhydrous silica; ethylcellulose - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate; ethylcellulose; colloidal anhydrous silica; guar gum; magnesium stearate; disodium edetate - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - clonazepam (unii: 5pe9fde8gb) (clonazepam - unii:5pe9fde8gb) - clonazepam 0.5 mg - seizure disorders clonazepam tablets, usp are useful alone or as an adjunct in the treatment of the lennox-gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. in patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. some loss of effect may occur during the course of clonazepam treatment (see precautions, loss of effect ). panic disorder clonazepam tablets, usp are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in dsm-v. panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. the efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the dsm-iiir category of panic disorder (see clinical pharmacology, clinical trials

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; hypromellose; calcium hydrogen phosphate; maize starch; purified talc; macrogol 400 - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronide has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.